Bristol Myers: European Commission approves cancer drug
(CercleFinance.com) - Bristol Myers Squibb has received European Commission approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) with two cycles of chemotherapy for the first-line treatment of metastatic non-small cell lung cancer.
This approval is based on the results of the CheckMate -9LA Phase 3 trial showing superior overall survival in patients with metastatic non-small cell lung cancer, regardless of PD-L1 expression or tumour histology.
The European Commission's decision marks the first time that dual immunotherapy with limited chemotherapy is approved for non-small cell lung cancer patients in the EU.
Opdivo plus Yervoy-based combinations are now indicated in the EU for three different types of advanced cancer: non-small cell lung cancer, melanoma and renal cell carcinoma.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
This approval is based on the results of the CheckMate -9LA Phase 3 trial showing superior overall survival in patients with metastatic non-small cell lung cancer, regardless of PD-L1 expression or tumour histology.
The European Commission's decision marks the first time that dual immunotherapy with limited chemotherapy is approved for non-small cell lung cancer patients in the EU.
Opdivo plus Yervoy-based combinations are now indicated in the EU for three different types of advanced cancer: non-small cell lung cancer, melanoma and renal cell carcinoma.
Copyright (c) 2020 CercleFinance.com. All rights reserved.